Blood News and Research

RSS

Causal role proposed for vitamin D in blood pressure

The results of a mendelian randomisation analysis suggest a causal link between low levels of vitamin D and increased blood pressure.

30 Jun 2014

Omega-3 PUFAs offer an affordable way to reduce effects of traumatic brain, spinal cord injuries

The omega-3 polyunsaturated fatty acids (PUFAs) found in seafood and marine oils called EPA and DHA may offer a simple, affordable way to reduce the effects of traumatic brain and spinal cord injuries by decreasing inflammation and nerve cell damage.

30 Jun 2014

Affimed Therapeutics files Form F-1 registration statement for public offering of common stock

Affimed Therapeutics today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common shares.

30 Jun 2014

Switching off a single gene converts human gastrointestinal cells into insulin-producing cells

By switching off a single gene, scientists at Columbia University's Naomi Berrie Diabetes Center have converted human gastrointestinal cells into insulin-producing cells, demonstrating in principle that a drug could retrain cells inside a person's GI tract to produce insulin.

30 Jun 2014

Almonds keep blood vessels healthy, reduce risk of heart disease

Scientists have found that eating almonds in your diet can reduce the risk of heart disease by keeping blood vessels healthy.

30 Jun 2014

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug.

28 Jun 2014

American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

The American Academy of Ophthalmology – the world's largest association of eye physicians and surgeons – is reminding the public that it does not recommend marijuana or other cannabis products for the treatment of glaucoma.

28 Jun 2014

GNS automated data analytics can predict future risk of metabolic syndrome in patients

Research published today in The American Journal of Managed Care demonstrates that analysis of patient records using state-of-the-art data analytics can predict future risk of metabolic syndrome.

28 Jun 2014

Menopause-related changes in sex hormones linked to greater risk for heart disease

As hormone levels change during the transition to menopause, the quality of a woman's cholesterol carriers degrades, leaving her at greater risk for heart disease, researchers at the University of Pittsburgh Graduate School of Public Health discovered.

28 Jun 2014

Newly identified compound may halt progression of Alzheimer's disease

Without a steady supply of blood, neurons can't work. That's why one of the culprits behind Alzheimer's disease is believed to be the persistent blood clots that often form in the brains of Alzheimer's patients, contributing to the condition's hallmark memory loss, confusion and cognitive decline.

28 Jun 2014

Study validates telemedicine approach to ROP screening

Trained non-physician evaluators who studied retinal images transmitted to computer screens at a remote central reading center successfully identified newborn infants likely to require a specialized medical evaluation for retinopathy of prematurity (ROP), a leading cause of treatable blindness.

28 Jun 2014

Weak hospice oversight makes safety problems hard to identify

The typical hospice undergoes a full government inspection about once every six years, according to The Washington Post, making it one of the least scrutinized areas of U.S. health care.

28 Jun 2014

New data analysis technique improves monitoring of kidney patients

A new data analysis technique radically improves monitoring of kidney patients, according to a University of Leeds-led study, and could lead to profound changes in the way we understand our health.

28 Jun 2014

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal.

28 Jun 2014

Non-surgical gum disease treatment reduces thickness of wall of arteries

A simple non-surgical gum disease treatment markedly reduces the thickness of the wall of the arteries, a risk factor for heart disease, according to a first of its kind study among Aboriginal Australians.

28 Jun 2014

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL).

28 Jun 2014

Ohm receives U.S. FDA approval to manufacture and market Valsartan

Ohm Laboratories, Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced today that Ohm has received approval from the U.S. Food and Drug Administration to manufacture and market Valsartan 40 mg, 80 mg, 160 mg, and 320 mg tablets on an exclusive basis.

27 Jun 2014

EMA CHMP adopts positive opinion for Bristol-Myers Squibb’s Daklinza for HCV treatment

Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.

27 Jun 2014

China Biologic prices follow-on offering of common stock at $38.00 per share

China Biologic Products, Inc., a leading plasma-based biopharmaceutical company in China, today announced the pricing of a follow-on offering of 1,550,000 shares of common stock at a public offering price of $38.00 per share.

27 Jun 2014

Blood News and Research

Causal role proposed for vitamin D in blood pressure

Omega-3 PUFAs offer an affordable way to reduce effects of traumatic brain, spinal cord injuries

Affimed Therapeutics files Form F-1 registration statement for public offering of common stock

Switching off a single gene converts human gastrointestinal cells into insulin-producing cells

Almonds keep blood vessels healthy, reduce risk of heart disease

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

GNS automated data analytics can predict future risk of metabolic syndrome in patients

Menopause-related changes in sex hormones linked to greater risk for heart disease

Newly identified compound may halt progression of Alzheimer's disease

Study validates telemedicine approach to ROP screening

Weak hospice oversight makes safety problems hard to identify

New data analysis technique improves monitoring of kidney patients

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

Non-surgical gum disease treatment reduces thickness of wall of arteries

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Ohm receives U.S. FDA approval to manufacture and market Valsartan

EMA CHMP adopts positive opinion for Bristol-Myers Squibb’s Daklinza for HCV treatment

China Biologic prices follow-on offering of common stock at $38.00 per share

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News